Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 3
Submit an article Journal homepage
179
Views
5
CrossRef citations to date
0
Altmetric
Letter

Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia

Laura CannellaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Giuseppina LoglisciDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Mauro NanniDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Maria Rosaria de CuiaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Gioia ColafigliDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Adriano SalaroliDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Alessandra SerraoDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Giuliana AlimenaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
&
Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, ItalyCorrespondence[email protected]
 show all
Pages 497-498 | Received 04 Jul 2011, Accepted 14 Aug 2011, Published online: 29 Sep 2011

References

  • Cortes JE, Talpaz M, Giles F, . Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101: 3794–3800.
  • O'Dwyer ME, Mauro MJ, Blasdel C, . Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103:451–455.
  • Baccarani M, Cortes J, Pane F, . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
  • Deininger MW, Cortes J, Paquette R, . The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007;110:1509–1519.
  • Jabbour E, Kantarjian HM, Abruzzo LV, . Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007;110:2991–2995.
  • Feldman E, Najfeld V, Schuster M, . The emergence of Ph-, trisomy -8 + cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003;31:702–707.
  • Zaccaria A, Valenti AM, Donti E, . Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica 2007;92:564–565.
  • Baldazzi C, Luatti S, Marzocchi G, . Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leuk Res 2009;33:e218–e220.
  • De Melo VA, Milojkovic D, Khorashad JS, . Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. Blood 2007;110:3086–3087.
  • Fabarius A, Haferlach C, Muller MC, . Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukaemia patients after imatinib failure. Haematologica 2007;92:834–837.
  • Verma D, Kantarjian H, Shan J, . Survival outcome for clonal evolution in chronic myeloid leukaemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010;116:2673–2681.
  • Kantarjian H, Shah NP, Hochhaus A, . Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
  • Saglio G, Kim DW, Issaragrisil S, . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–2259.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.